EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects

Feng Zhang, Zhuqing Li, Yanxin Wang, Chao Li, Chengzhi Lu

Cardiovascular Innovations and Applications · 2025 · 10 (1)

DOI: 10.15212/cvia.2024.0063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Innovations and Applications, 2025. Verfasst von Feng Zhang und 4 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and coronary artery disease, and is closely associated with the high incidence and mortality of heart failure in people with diabetes. DCM causes microvascular disease, myocardial metabolic disorder, and myocardial fibrosis, thereby leading to left ventricular remodeling, diastolic and/or systolic dysfunction, and eventually progressing to congestive heart failure. Recent studies have highlighted the crucial roles of mitochondrial dysfunction in the pathogenesis of DCM, including aspects such as glucose-lipid metabolic disorder, oxidative stress damage, calcium regulation disorder, respiratory chain uncoupling, kinetic imbalance, and mitochondrial DNA damage. Increasing numbers of targets and drugs are being identified to ameliorate mitochondrial dysfunction and consequently slow DCM progression. This article reviews the newly identified targets and drugs in the past decade, to provide new insights for DCM prevention and treatment.

Zitieren

APA

Zhang, F., Li, Z., Wang, Y., Li, C., & Lu, C. (2025). Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects. Cardiovascular Innovations and Applications, 10(1). https://doi.org/10.15212/cvia.2024.0063

Vancouver

Zhang F, Li Z, Wang Y, Li C, Lu C. Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects. Cardiovascular Innovations and Applications. 2025;10(1). doi:10.15212/cvia.2024.0063

BibTeX
@article{Zhang2025,
  author = {Zhang, Feng and Li, Zhuqing and Wang, Yanxin and Li, Chao and Lu, Chengzhi},
  title = {Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects},
  journal = {Cardiovascular Innovations and Applications},
  year = {2025},
  volume = {10},
  number = {1},
  doi = {10.15212/cvia.2024.0063}
}
Kostenlos starten →